A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Inclusion Criteria

• •\>/= 65 years old
• •documented diagnosis of lung, breast, or ovarian cancer, or NHL
• •scheduled to receive one of 15 standard chemotherapy regimens
• •chemotherapy naive OR have received adjuvant therapy AND/OR have no more than one regimen of chemotherapy for metastatic disease
• •life expectancy of at least 3 months
• •ECOG performance status \</=2
• •adequate renal and hematologic function
• •informed consent for participation in the study prior to any study specific procedures
• •unstable/uncontrolled cardiac conditions or hypertension
• •active infection
• •subject is currently enrolled or has not yet completed at least 30 days since ending other investigational device or drug trial or is receiving other investigational agents